1. Home
  2. NVAX vs ATRC Comparison

NVAX vs ATRC Comparison

Compare NVAX & ATRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVAX
  • ATRC
  • Stock Information
  • Founded
  • NVAX 1987
  • ATRC 2000
  • Country
  • NVAX United States
  • ATRC United States
  • Employees
  • NVAX N/A
  • ATRC N/A
  • Industry
  • NVAX Biotechnology: Biological Products (No Diagnostic Substances)
  • ATRC Medical/Dental Instruments
  • Sector
  • NVAX Health Care
  • ATRC Health Care
  • Exchange
  • NVAX Nasdaq
  • ATRC Nasdaq
  • Market Cap
  • NVAX 1.3B
  • ATRC 1.6B
  • IPO Year
  • NVAX 1995
  • ATRC 2005
  • Fundamental
  • Price
  • NVAX $7.84
  • ATRC $37.66
  • Analyst Decision
  • NVAX Hold
  • ATRC Strong Buy
  • Analyst Count
  • NVAX 6
  • ATRC 10
  • Target Price
  • NVAX $15.00
  • ATRC $49.60
  • AVG Volume (30 Days)
  • NVAX 8.6M
  • ATRC 705.3K
  • Earning Date
  • NVAX 08-06-2025
  • ATRC 07-29-2025
  • Dividend Yield
  • NVAX N/A
  • ATRC N/A
  • EPS Growth
  • NVAX N/A
  • ATRC N/A
  • EPS
  • NVAX 2.54
  • ATRC N/A
  • Revenue
  • NVAX $1,078,718,000.00
  • ATRC $499,946,000.00
  • Revenue This Year
  • NVAX $52.02
  • ATRC $14.63
  • Revenue Next Year
  • NVAX N/A
  • ATRC $12.62
  • P/E Ratio
  • NVAX $3.08
  • ATRC N/A
  • Revenue Growth
  • NVAX 9.22
  • ATRC 16.28
  • 52 Week Low
  • NVAX $5.01
  • ATRC $23.97
  • 52 Week High
  • NVAX $15.22
  • ATRC $43.11
  • Technical
  • Relative Strength Index (RSI)
  • NVAX 48.26
  • ATRC 64.88
  • Support Level
  • NVAX $7.57
  • ATRC $34.91
  • Resistance Level
  • NVAX $10.64
  • ATRC $36.20
  • Average True Range (ATR)
  • NVAX 0.72
  • ATRC 1.15
  • MACD
  • NVAX -0.07
  • ATRC 0.03
  • Stochastic Oscillator
  • NVAX 29.47
  • ATRC 95.16

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

About ATRC AtriCure Inc.

AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.

Share on Social Networks: